# Krystal Biotech, Inc.: overview

KRYS · Nasdaq · CIK 1711279 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/krys.md) · [Financials](/companies/krys/financials.md) · [Filings](/companies/krys/filings.md) · [Insiders](/companies/krys/insiders.md)

Latest reported revenue: [$119.2m](/filings/0001711279-26-000057.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 3, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001711279-26-000057).

## Last eight quarters

| Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [83.8](/filings/0001711279-25-000087.md) | [91.1 d](/filings/0001711279-26-000016.md) | [88.2](/filings/0001711279-26-000043.md) | [96.0](/filings/0001711279-26-000057.md) | [97.8](/filings/0001711279-25-000087.md) | [107 d](/filings/0001711279-26-000016.md) | [116](/filings/0001711279-26-000043.md) | [119](/filings/0001711279-26-000057.md) |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | [26.8%](/filings/0001711279-25-000087.md) | [45.4% d](/filings/0001711279-26-000016.md) | [41.1%](/filings/0001711279-26-000043.md) | [41.0%](/filings/0001711279-26-000057.md) | [42.3%](/filings/0001711279-25-000087.md) | [41.3% d](/filings/0001711279-26-000016.md) | [46.1%](/filings/0001711279-26-000043.md) | [49.0%](/filings/0001711279-26-000057.md) |
| Net margin | % | [32.4%](/filings/0001711279-25-000087.md) | [49.9% d](/filings/0001711279-26-000016.md) | [40.5%](/filings/0001711279-26-000057.md) | [39.9%](/filings/0001711279-26-000057.md) | [81.2%](/filings/0001711279-25-000087.md) | [48.0% d](/filings/0001711279-26-000016.md) | [48.1%](/filings/0001711279-26-000057.md) | [45.9%](/filings/0001711279-26-000057.md) |
| Diluted EPS | $ per share | [0.91](/filings/0001711279-25-000087.md) | not reported | [1.20](/filings/0001711279-26-000043.md) | [1.29](/filings/0001711279-26-000057.md) | [2.66](/filings/0001711279-25-000087.md) | not reported | [1.83](/filings/0001711279-26-000043.md) | [1.79](/filings/0001711279-26-000057.md) |
| Free cash flow | $m | [57.8 d](/filings/0001711279-25-000087.md) | [52.0 d](/filings/0001711279-26-000016.md) | [24.8](/filings/0001711279-26-000043.md) | [50.8 d](/filings/0001711279-26-000057.md) | [38.0 d](/filings/0001711279-25-000087.md) | [75.4 d](/filings/0001711279-26-000016.md) | [73.2](/filings/0001711279-26-000043.md) | [71.2 d](/filings/0001711279-26-000057.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure.

## Last five fiscal years

| Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [0.0](/filings/0001711279-24-000005.md) | [0.0](/filings/0001711279-25-000008.md) | [50.7](/filings/0001711279-26-000016.md) | [291](/filings/0001711279-26-000016.md) | [389](/filings/0001711279-26-000016.md) |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | not reported | not reported | [(216.2%)](/filings/0001711279-26-000016.md) | [22.6%](/filings/0001711279-26-000016.md) | [41.5%](/filings/0001711279-26-000016.md) |
| Net margin | % | not reported | not reported | [21.6%](/filings/0001711279-26-000016.md) | [30.7%](/filings/0001711279-26-000016.md) | [52.6%](/filings/0001711279-26-000016.md) |
| Diluted EPS | $ per share | [(3.13)](/filings/0001711279-24-000005.md) | [(5.49)](/filings/0001711279-25-000008.md) | [0.39](/filings/0001711279-26-000016.md) | [3.00](/filings/0001711279-26-000016.md) | [6.84](/filings/0001711279-26-000016.md) |
| Free cash flow | $m | [(116)](/filings/0001711279-24-000005.md) | [(154)](/filings/0001711279-25-000008.md) | [(101)](/filings/0001711279-26-000016.md) | [119](/filings/0001711279-26-000016.md) | [189](/filings/0001711279-26-000016.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/krys/insiders.md)

None in coverage.

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [FMR LLC](/funds/315066.md) | 2026-06-30 | $1.64bn | 4,418,197 |  | Added +44,210 |
| [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $1.55bn | 4,181,432 |  | Added +240,976 |
| [Avoro Capital Advisors LLC](/funds/1633313.md) | 2026-06-30 | $1.07bn | 2,888,888 |  | Unchanged |
| [VANGUARD PORTFOLIO MANAGEMENT LLC](/funds/2100121.md) | 2026-06-30 | $585.3m | 1,574,905 |  | Added +118,178 |
| [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $502.2m | 1,351,158 |  | Added +36,724 |
| [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $461.1m | 1,240,567 |  | Added +75,243 |
| [Soleus Capital Management, L.P.](/funds/1802630.md) | 2026-06-30 | $349.1m | 939,254 |  | Reduced −213,833 |
| [Capital World Investors](/funds/1422849.md) | 2026-06-30 | $289.1m | 777,843 |  | Reduced −46,877 |
| [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $259.8m | 698,993 |  | Added +55,018 |
| [Hood River Capital Management LLC](/funds/1578177.md) | 2026-06-30 | $246.6m | 663,375 |  | Added +43,789 |

## Recent filings

[All 508 filings](/companies/krys/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-10-15 | 07:02 ET | [8-K](/filings/0001711279-26-000064.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001711279-26-000064 |
| 2026-08-03 | 07:04 ET | [8-K](/filings/0001711279-26-000058.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001711279-26-000058 |
| 2026-08-03 | 07:03 ET | [10-Q](/filings/0001711279-26-000057.md) | Quarterly report, period 2026-06-30 | 0001711279-26-000057 |
| 2026-07-21 | 17:24 ET | [8-K](/filings/0001711279-26-000050.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001711279-26-000050 |
| 2026-05-20 | 20:08 ET | [8-K](/filings/0001711279-26-000047.md) | 5.07 Shareholder vote results | 0001711279-26-000047 |
| 2026-05-04 | 07:07 ET | [8-K](/filings/0001711279-26-000044.md) | 9.01 Financial statements and exhibits | 0001711279-26-000044 |
| 2026-05-04 | 07:06 ET | [10-Q](/filings/0001711279-26-000043.md) | Quarterly report, period 2026-03-31 | 0001711279-26-000043 |
| 2026-04-03 | 16:31 ET | [DEF 14A](/filings/0001711279-26-000036.md) | Proxy statement, period 2026-04-03 | 0001711279-26-000036 |
| 2026-02-17 | 07:06 ET | [8-K](/filings/0001711279-26-000018.md) | 2.02 Results of operations | 0001711279-26-000018 |
| 2026-02-17 | 07:05 ET | [10-K](/filings/0001711279-26-000016.md) | Annual report, period 2025-12-31 | 0001711279-26-000016 |

## Latest annual report

[Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001711279-26-000016.md), filed Feb 17, 2026.

## Forecast league

Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/cfad50a7-68f4-4f83-a0e7-41661aee5763)

## About the filer

- CIK: 1711279
- Tickers: KRYS
- Exchange: Nasdaq
- SIC code: 2836 Biological Products, (No Diagnostic Substances)
- State of incorporation: not reported
- Filer category: Large accelerated filer

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 30, 2026, 13:54 ET. No prices; not investment advice.